Press Releases

Date Title and Summary Additional Formats
Toggle Summary Clinical Data from NewLink Genetics' HyperAcute Prostate Cancer Immunotherapy Published in Journal of Immunotherapy
- Data Continues to Support the use of NewLink's HyperAcute® Immunotherapy to Elicit a Response in Tumor-Specific Antigens Common to both the Immunotherapy and the Patient's Tumor Cells -
View HTML
Toggle Summary NewLink Genetics Receives European Orphan Designation for Algenpantucel-L Immunotherapy to Treat Pancreatic Cancer
AMES, Iowa , Nov. 14, 2012 /PRNewswire/ --  NewLink Genetics Corporation (Nasdaq: NLNK) today announced that the European Commission (EC) has designated HyperAcute-Pancreas® Immunotherapy (algenpantucel-L) as an orphan medicinal product under Regulation (EC) No.
View HTML
Toggle Summary Lota S. Zoth joins NewLink's Board of Directors; heads Audit Committee
David J. Lundquist and Sarah Alexander step down from the Board
View HTML
Toggle Summary NewLink Genetics Corporation Reports Third Quarter 2012 Financial Results
AMES, IA -- (Marketwire) -- 10/31/12 -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today reported consolidated financial results for the third quarter of 2012.
View HTML
Toggle Summary NewLink Genetics Launches Phase 3 Clinical Trial of algenpantucel-L Immunotherapy in Patients with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
AMES, Iowa , Oct. 10, 2012 /PRNewswire/ --  NewLink Genetics Corporation (Nasdaq: NLNK) announces launching of an open-label, randomized, multi-institutional Phase 3 study in patients with borderline resectable or locally advanced unresectable pancreatic cancer.
View HTML
Toggle Summary NewLink Genetics Launches Adaptive Design Phase 2B/3 Clinical Trial of tergenpumatucel-L Immunotherapy in Patients with Non-Small Cell Lung Cancer
AMES, Iowa , Oct. 3, 2012 /PRNewswire/ --  NewLink Genetics Corporation (Nasdaq: NLNK) announces the launching of an open-label, randomized, multi-institutional adaptive design Phase2B/3 study to evaluate efficacy of its tergenpumatucel-L (HyperAcute® Lung) product candidate in patients with
View HTML
Toggle Summary NewLink to Present at 3rd Annual Cancer Immunotherapy Conference
AMES, Iowa , Oct. 2, 2012 /PRNewswire/ --  NewLink Genetics (NASDAQ:NLNK) today announced that the company will be presenting at the 3 rd Annual Cancer Immunotherapy: A Long-Awaited Reality conference taking place from 8:00 a.m. to 6:30 p.m. EDT on October 4, 2012 , at the New York Academy of
View HTML
Toggle Summary NewLink Announces an Investigator Initiated Phase 2 Study of Sipuleucel-T Plus Indoximod in the Treatment of Certain Men With Advanced Prostate Cancer
AMES, Iowa , Sept. 21, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics (Nasdaq:NLNK) announced today that it will begin an investigator initiated, randomized, double blind placebo controlled Phase 2 study entitled "Phase II Study of sipuleucel-T (PROVENGE ® ) plus indoximod (D-1MT/ NLG8189 ) in the
View HTML
Toggle Summary NewLink CEO to Participate in Panel Entitled "Innovation in Immunotherapy and Vaccines"
AMES, Iowa , Sept. 20, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics (Nasdaq:NLNK) announced today that Dr. Charles Link , Chairman and CEO, will participate in a panel discussion entitled "Innovation in Immunotherapy and Vaccines" at the University of Connecticut Stamford Campus on Monday September
View HTML
Toggle Summary NewLink Genetics Corporation Reports Second Quarter 2012 Financial Results
AMES, Iowa , Aug. 14, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today reported consolidated financial results for the second quarter of 2012, and provided an update on
View HTML